A platform for research: civil engineering, architecture and urbanism
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
VERSCHRAEGEN, C. F. (author) / LEVENBACK, C. (author) / VINCENT, M. (author) / WOLF, J. (author) / BEVERS, M. (author) / LOYER, E. (author) / KUDELKA, A. P. (author) / KAVANAGH, J. J. (author)
Annals of the New York Academy of Sciences ; 922 ; 349-351
2000-12-01
3 pages
Article (Journal)
Electronic Resource
English
Elsevier | 1984
|Laparoscopic tubal sterilization—complications
Elsevier | 1980
European Patent Office | 2023
|